Rhythm Pharmaceuticals Inc’s filing revealed that its Chief Human Resources Officer Cramer Pamela J. unloaded Company’s shares for reported $0.46 million on Apr 29 ’25. In the deal valued at $65.09 per share,7,031 shares were sold. As a result of this transaction, Cramer Pamela J. now holds 19,209 shares worth roughly $1.18 million.
Then, Mazabraud Yann sold 6,745 shares, generating $438,946 in total proceeds. Upon selling the shares at $65.08, the EVP, Head of International now owns 37,655 shares.
Before that, YANN MAZZABRAUD bought 6,745 shares. Rhythm Pharmaceuticals Inc shares valued at $434,445 were divested by the Officer at a price of $64.41 per share.
BofA Securities upgraded its Rhythm Pharmaceuticals Inc [RYTM] rating to a Buy from a a Neutral in a research note published recently. Jefferies began covering RYTM with “Buy” recommendation on January 02, 2025. Oppenheimer started covering the stock on December 20, 2024. It rated RYTM as “an Outperform”.
Price Performance Review of RYTM
On Monday, Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] saw its stock jump 2.20% to $61.25. Over the last five days, the stock has gained 3.88%. Rhythm Pharmaceuticals Inc shares have risen nearly 9.41% since the year began. Nevertheless, the stocks have risen 54.67% over the past one year. While a 52-week high of $68.58 was reached on 05/02/25, a 52-week low of $35.17 was recorded on 04/07/25.
How much short interest is there in Rhythm Pharmaceuticals Inc?
A steep rise in short interest was recorded in Rhythm Pharmaceuticals Inc stocks on 2025-04-30, growing by 0.2 million shares to a total of 4.85 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 4.66 million shares. There was a rise of 4.05%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 21, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
